Shuttle Pharmaceuticals Gears Up for 2024 ThinkEquity Conference
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH), a pioneering company in the specialty pharmaceutical industry, is set to make waves at the upcoming ThinkEquity Conference. The event promises to be an exciting platform as Dr. Anatoly Dritschilo, the company’s Chief Executive Officer, will take the stage on October 30, 2024, at 8:30 am ET. This is a remarkable opportunity for investors to hear about the company's latest advancements in cancer treatment technologies.
Understanding the Significance of the ThinkEquity Conference
The ThinkEquity Conference is known for bringing together industry leaders, institutional investors, and innovative thinkers to discuss cutting-edge developments and financial strategies. It provides a vital opportunity for pharmaceutical companies like Shuttle Pharmaceuticals to showcase their promising projects and strengthen relationships with potential investors.
Insights on Ropidoxuridine
During his presentation, Dr. Dritschilo will share significant updates on the company's notable Phase 2 Clinical Trial of Ropidoxuridine, specifically targeting patients suffering from glioblastoma. This harmful brain cancer poses treatment challenges due to its aggressive nature and the lack of effective cures. Through ongoing research, Shuttle Pharmaceuticals aims to improve treatment methodologies and enhance patient outcomes.
Innovations in Prostate Cancer Treatment
Furthermore, the CEO will highlight Shuttle Diagnostics, Inc., which is dedicated to developing crucial predictive biomarkers that can greatly influence the outcomes for prostate cancer patients following radiation therapy. The creation of a new PSMA ligand for theranostic applications will also be discussed, showcasing the company's commitment to personalized medicine and innovative cancer care.
Event Details
Conference Date: Wednesday, October 30, 2024
Time: 8:30 am ET
Location: Mandarin Oriental Hotel, New York
Webcast Information
For those unable to attend in person, Shuttle Pharmaceuticals will provide a webcast of the presentation, which will be accessible from their official website. Attendees can look forward to a detailed overview of the company's operations and future directions.
In-Person Meetings with Investors
Management will also engage in one-on-one meetings at the conference, giving investors a chance to discuss their interests directly with the leadership team. Interested parties are encouraged to schedule meetings through their respective representatives at ThinkEquity.
About Shuttle Pharmaceuticals
Founded in 2012 by a team from the Georgetown University Medical Center, Shuttle Pharmaceuticals is on a mission to revolutionize cancer treatment through its specialty pharmaceutical innovations. The company focuses on enhancing the efficacy of radiation therapy (RT) while reducing its side effects. By advancing radiation sensitizers, Shuttle Pharmaceuticals aims to boost cancer cure rates and extend survival durations, aiming to deliver higher quality of life for patients.
Contact Details
For inquiries regarding Shuttle Pharmaceuticals, please reach out to:
Anatoly Dritschilo, M.D., CEO
Phone: 240-403-4212
Email: info@shuttlepharma.com
Investor Relations
For investor-related questions, please contact:
Lytham Partners, LLC
Robert Blum
Phone: 602-889-9700
Email: shph@lythampartners.com
Frequently Asked Questions
What is the ThinkEquity Conference?
The ThinkEquity Conference is an event that gathers institutional investors, corporate clients, and industry professionals to discuss financial strategies and innovations in various fields, including pharmaceuticals.
Who will present at the conference on behalf of Shuttle Pharmaceuticals?
Dr. Anatoly Dritschilo, CEO of Shuttle Pharmaceuticals, will be presenting at the conference.
What is Ropidoxuridine?
Ropidoxuridine is a drug currently undergoing clinical trials by Shuttle Pharmaceuticals for the treatment of glioblastoma, a particularly aggressive form of brain cancer.
How can investors arrange a meeting with Shuttle Pharmaceuticals management?
Investors should contact their ThinkEquity representative to arrange meetings with the management team during the conference.
What are Shuttle Pharmaceuticals’ main goals?
The main goals of Shuttle Pharmaceuticals are to improve the outcomes for cancer patients undergoing radiation therapy while maximizing treatment efficacy and minimizing side effects.
